Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07163221 · ClinicalTrials.gov registry record · NA

At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]

A NA study of Rheumatoid Arthritis (RA), sponsored by SecondWave Systems.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
5
Study locations

NCT07163221: Recruiting NA study of Rheumatoid Arthritis (RA), sponsored by SecondWave Systems.

NCT07163221 is a NA study of Rheumatoid Arthritis (RA) that is actively recruiting participants, run by SecondWave Systems. The registered enrollment target is 60 participants, below the 264-participant average among 17 other Rheumatoid Arthritis (RA) trials with a reported enrollment target (77% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07163221, a NA study of Rheumatoid Arthritis (RA), is actively recruiting participants, sponsored by SecondWave Systems.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
5
Study locations

Study Summary

The At-Home ULTRA Study will evaluate performance of the MINI system as indicated for the treatment of adults with active, moderate to severe rheumatoid arthritis who are inadequate responders or are intolerant to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biologic DMARDs (bDMARDs), or targeted synthetic DMARDs (tsDMARDs). The non-invasive study device delivers ultrasound stimulation to the spleen to reduce inflammation. The study will enroll at least 60 participants at up to 8 sites. There will be three arms consisting of two active stimulation groups (treatment) and one non-active stimulation group (sham-control). After completing the double-blinded primary endpoint assessment period at Week 12, there will be a one-way crossover of control participants to active stimulation and an additional 12 week follow-up with all participants to evaluate long-term outcomes.

Primary Outcome

A decrease in Disease Activity Score indicates an improved outcome

Conditions Studied

Interventions

  • DEVICE Non-invasive ultrasound stimulation of the spleen - Treatment Setting 1
  • DEVICE Non-invasive ultrasound stimulation of the spleen - Treatment Setting 2
  • DEVICE Sham ultrasound stimulation (control)
  • DRUG Conventional Synthetic DMARD

Study Locations (5)

California

  • Medvin Clinical Research - Covina
  • Southland Arthritis & Osteoporosis Medical Center - Temecula

Arizona

  • Arizona Arthritis and Rheumatology Associates P.C. - Glendale

Colorado

  • University of Colorado - Aurora

Minnesota

  • University of Minnesota Medical School, Division of Rheumatic and Autoimmune Diseases - Minneapolis

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-11-03
Est. Completion 2026-11
Phase NA
SecondWave Systems

3 total trials

What NCT07163221 shows while recruiting

NCT07163221 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 264-participant average among 17 other Rheumatoid Arthritis (RA) trials with a reported enrollment target (77% lower).

The record links to 1 condition, with Rheumatoid Arthritis (RA) appearing as the primary indexed condition, and to 4 interventions - of which Non-invasive ultrasound stimulation of the spleen - Treatment Setting 1 is the first listed.

NCT07163221 lists 5 locations in 4 states (California, Arizona, Colorado).

Frequently Asked Questions

What is clinical trial NCT07163221 about?

NCT07163221 is a clinical study titled "At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]". The At-Home ULTRA Study will evaluate performance of the MINI system as indicated for the treatment of adults with active, moderate to severe rheumatoid arthritis who are inadequate responders or are intolerant to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biologic DMA...

What is the current status of trial NCT07163221?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-11-03. Estimated completion is 2026-11.

What conditions does trial NCT07163221 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis (RA).

What interventions are being tested in trial NCT07163221?

The interventions under investigation include: Non-invasive ultrasound stimulation of the spleen - Treatment Setting 1 (DEVICE), Non-invasive ultrasound stimulation of the spleen - Treatment Setting 2 (DEVICE), Sham ultrasound stimulation (control) (DEVICE), Conventional Synthetic DMARD (DRUG).

Who is sponsoring clinical trial NCT07163221?

This trial is sponsored by SecondWave Systems, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07163221 being conducted?

This trial has 5 study locations across Arizona, California, Colorado, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rheumatoid Arthritis (RA)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07163221's enrollment target sits among peer trials

60 12th of 17 higher than 6 of 17 other Rheumatoid Arthritis (RA) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rheumatoid Arthritis (RA) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07163221, the US trial registry maintained by the National Library of Medicine. NCT07163221 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.